Access cutting-edge non-small cell lung cancer treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access non-small cell lung cancer specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-small cell lung cancer treatment provided free
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Sponsor: Mirati Therapeutics Inc.
Check if you qualify for this non-small cell lung cancer clinical trial in Chicago, IL
If you're searching for non-small cell lung cancer treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.